After getting the authentication, the company is planning to market this product for the treatment of moderate to severe symptoms of vulvae and vaginal waste accompanied by the menopause. The company has sincerely worked very closely with the Food and Drugs Administration authorities as the review process for its Bijuva vaginal cream product advanced even after the non-approvable letter given by the agency. The company is quite confident that the pending matters at the agency level would shortly be resolved as revealed by the President and CEO of Duramed Research of Duramed Pharmaceuticals Inc, USA.

The company is already committed to the estrogen therapy markets and is presently promoting Cenestin o.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablets directly to the doctors or the physicians through the company’s sales force of over 200 persons for Women’s Healthcare products. This drug competes in the HT-Hormone Therapy markets and provides offers the women willing to take hormone products with the plant-derived options.